Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636112 | 0.89 | PTGIR (0.38) | PTGDR2PTGDRPTGIRALOX5APPDE10A | |
| SCHEMBL3327259 | 0.86 | PTGDR2 (0.42) | PTGDR2PTGDRPTGIRALOX5APPDE10A | |
| SCHEMBL3327331 | 0.76 | PTGIR (0.36) | PTGDR2PTGDRPTGIRPDE10ASMN1; SMN2 | |
| SCHEMBL14176165 | 0.74 | PTGDR2 (0.44) | PTGDR2PTGDRPTGIRALOX5APAKR1C3 | |
| SCHEMBL3567666 | 0.72 | PTGDR2 (0.42) | PTGDR2PTGDRPTGIRPDE10AHDAC1 | |
| SCHEMBL1786702 | 0.68 | PTGDR2 (0.85) | PTGDR2PTGDRPTGIR | |
| SCHEMBL4720632 | 0.65 | HDAC1 (0.51) | PDE10ALMNASMN1; SMN2HDAC1HDAC2 | |
| SCHEMBL3577485 | 0.64 | TSHR (0.38) | PTGDR2PTGDRPTGIRPDE10ALMNA | |
| SCHEMBL3345145 | 0.63 | PTGDR2 (0.41) | PTGDR2PTGDRPTGIRALOX5APPDE10A | |
| SCHEMBL7554596 | 0.63 | GABRB2 (0.48) | PTGDR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | PTGDR2 293/4885PTGDR 249/4885PTGIR 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.